All treatments
Treatment
Eto-GRY® 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase III and phase IV (Integrated)
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC (KEYVIBE-006)
This study is looking at new ways to treat advanced lung cancer that can't be removed by surgery. It compares a new combination of medicines with a standard treatment, both given with chemotherapy and radiotherapy, to see which works best.
For: Non-small cell lung cancerSpain · Italy · Germany - AuthorisedTherapeutic exploratory (Phase II)
Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC
This study is looking at a new way to treat an advanced type of lung cancer called extensive stage small cell lung cancer. It combines standard treatments like chemotherapy and radiotherapy with a new drug called Durvalumab (Imfinzi) to see if it can stop the cancer from growing for longer.
For: extensive stage small cell lung cancer (SCLC)Germany